KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On March16, 2017, KalVista Pharmaceuticals, Inc. (the Company)
reported its financial results for the quarter ended January31,
2017. A copy of the press release issued by the Company is
furnished as Exhibit 99.1 to this report.
The information furnished with Item 2.02 of this report,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into
any other filing under the Exchange Act or under the Securities
Act of 1933, as amended, except as expressly set forth by
specific reference in such a filing.
| Item9.01. | Financial Statements and Exhibits. |
|
Exhibit Number |
Description |
|
| 99.1 | Press release dated March16, 2017. |
2
About KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001. KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Recent Trading Information
KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) closed its last trading session down -0.08 at 8.26 with 14,422 shares trading hands.
